PDCD1 and breast carcinoma: Especially for monoclonal programmed death 1 (PD1) and PD1 ligand (PDL1) antibody-mediated immune checkpoint blockade (ICB) therapy has shown exceptional success in treating many cancers, including melanoma, lung cancer, breast cancer, and non-small cell cancer 5-9.